Anti-clotting drug significantly reduces bleeding events in patients with atrial fibrillation, clinical trial shows
Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...
Science Daily6h
Study shows anti-clotting drug reduced bleeding events in patients with atrial fibrillation
Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...
MedPage Today3h
Injectable Anticoagulant Substantially Cuts Bleeding Risk in Afib
For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...
News Medical on MSN22h
New Factor XI inhibitor shows superior safety in treating atrial fibrillation
Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...
ENDPOINTS NEWS12h
An­thos' de­tailed mid-stage da­ta back its an­ti­co­ag­u­lant, but can the drug suc­ceed where Bay­er's failed?
Anthos Therapeutics' abelacimab shows lower bleeding risk vs Xarelto in atrial fibrillation trial, with 62% reduction in ...